2 Information about idelalisib
|
Marketing authorisation indication |
Idelalisib (Zydelig, Gilead) has a marketing authorisation 'as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment'. |
|---|---|
|
Dosage in the marketing authorisation |
Idelalisib is administered orally at a dose of 150 mg, twice daily. Treatment is continued until disease progression or unacceptable toxicity. |
|
Price |
The list price for idelalisib is £3,114.75 per pack of 60 x 150 mg film-coated tablets (excluding VAT, company submission). The company has a commercial arrangement for idelalisib, which would apply if the technology had been recommended. |